在1型糖尿病中监测免疫调节策略
Balasubramanian Krishnamurthy1,2, Matthew Lacorcia1, Thomas W H Kay1,2
1Immunology and Diabetes Unit, St Vincent's Institute, Fitzroy, VIC, Australia.
Frontiers in immunology
|June 22, 2023
概括
1型糖尿病 (T1D) 是一种T细胞自身免疫性疾病. 目前的治疗方法提供暂时休息,但未来的治疗方法旨在进行早期干预,更好地预测疾病进展和治疗成功.
科学领域:
- 免疫学 免疫学 免疫学
- 内分泌学 在内分泌学.
- 自免疫性疾病 自免疫性疾病
背景情况:
- 1型糖尿病 (T1D) 是一种T细胞介导的自身免疫性疾病.
- 目前针对免疫细胞和细胞因子的免疫疗法只能提供短期的疾病修饰.
- 了解T细胞反应对于T1D管理至关重要.
研究的目的:
- 审查从T1D免疫调节试验中学到的经验教训.
- 讨论分析抗原特异性T细胞的进展.
- 突出新型生物标志物和测试对T1D预测和治疗的潜力.
主要方法:
- 对T1D的短期治疗试验的审查.
- 对抗原特异性T细胞测定和表位发现进展的分析.
- 在单细胞水平上讨论高维造型 (基因,蛋白质,TCR).
主要成果:
- 短期免疫调节治疗可以暂时停止T1D活动.
- 标准化T细胞测定和表位发现面临挑战.
- 高维单细胞概况为生物标志物发现提供了前景.
结论:
- 预计在早期T1D中使用有效的疾病修饰剂.
- 针对抗原特异性T细胞的不断发展的试验将改善T1D预测.
- 对T细胞反应的更好理解将指导T1D的治疗干预.
相关概念视频
Diabetes: Management and Pharmacotherapy
319
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
319
Diabetes Mellitus: Overview and Type I Subtype
2.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.8K
Insulin: Dosing Regimen and Adverse Effects
214
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
214
Diabetes Mellitus: Type 2 and Gestational
2.6K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.6K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
201
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
201


